Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers

Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers
Herzuma, a biosimilar to Genentech's Herceptin (trastuzumab), is now available in the U.S. for the same indications as the reference therapy, including for the treatment of HER2-positive breast cancers and stomach cancers. The treatment was approved by the U.S. Food and Drug Administration (FDA) in December 2018, the same year it was approved by the European Medicines Agency. “We are proud to make Herzuma available to patients in the U.S. living with HER2-positive breast and gastric cancers, and their providers,” Brendan O’Grady, executive vice president of North America commercial at Teva, said in a press release. Herzuma is a Herceptin biosimilar developed by Teva Pharmaceuticals and Celltrion Healthcare. Biosimilars are medical products that are nearly identical to approved therapies, but are manufactured by a different company after the patent for the original
Subscribe or to access all post and page content.